| 1 |
NCT00103597 |
Completed |
Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy |
- Parkinson's Disease
- Multiple System Atrophy
- Orthostatic Hypotension
|
- Drug: Fludrocortisone
- Drug: Domperidone
- Behavioral: Conservative Measures for Orthostatic Hypotension
|
Interventional
|
Phase 1 |
- Royal Brisbane and Women's Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Efficacy of conservative treatment, domperidone, and fludrocortisone for patient's subjective symptoms of orthostatic hypotension, and on objective autonomic testing
|
50 |
All |
40 Years to 95 Years (Adult, Older Adult) |
NCT00103597 |
2004/135 |
|
January 2005 |
|
September 2005 |
February 14, 2005 |
October 20, 2005 |
|
- Royal Brisbane and Women's Hospital
Brisbane, Queensland, Australia
|
|
| 2 |
NCT02071459 |
Recruiting |
Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA |
|
- Drug: L-Threo DOPS
- Drug: placebo
|
Interventional
|
Phase 2
Phase 3 |
- University Hospital, Toulouse
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Evaluate the efficacy of long term efficacy of L-threo DOPS
- efficacy of L-ThreoDOPS on symptomatic OH
- effects of L-Threo DOPS on motor symptoms
- (and 2 more...)
|
108 |
All |
30 Years to 80 Years (Adult, Older Adult) |
NCT02071459 |
12 554 01
12-018-0200 |
DOPS-AMS |
February 2014 |
December 2018 |
December 2018 |
February 25, 2014 |
March 7, 2017 |
|
- Centre hospitalier d'Angers
Angers, France - CHU bordeaux
Bordeaux, France - CHU de Clermont-Ferrand
Clermont-Ferrand, France - (and 10 more...)
|
|
| 3 |
NCT00758849 |
Unknown † |
Fipamezole in Neurogenic Orthostatic Hypotension |
- Symptomatic Neurogenic Orthostatic Hypotension (NOH)
- Parkinson's Disease
- Multiple System Atrophy
|
- Drug: Placebo
- Drug: Fipamezole
|
Interventional
|
Phase 2 |
- Juvantia Pharma Ltd
- Santhera Pharmaceuticals
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To compare the efficacy of fipamezole with that of placebo on orthostatic hypotension as assessed by blood pressure response to orthostatism.
- To compare the efficacy of fipamezole with that of placebo on heart rate (HR) response to orthostatism.
- To compare the efficacy of fipamezole with that of placebo on clinical symptoms.
- (and 2 more...)
|
24 |
All |
30 Years to 80 Years (Adult, Older Adult) |
NCT00758849 |
SNT-II-005 |
Foehn |
September 2008 |
May 2009 |
May 2009 |
September 25, 2008 |
October 1, 2008 |
|
- Hôpital du Haut Lévêque, CHU de Bordeaux
Bordeaux, France - Hôpital de la Cavale Blanche, CHU Brest
Brest, France - Hôpital Purpan CIC du CHU de Toulouse
Toulouse, France - Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa
Lisbon, Portugal
|
|
| 4 |
NCT01316666 |
Completed |
Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension |
- Orthostatic Hypotension
- Pure Autonomic Failure
- Multiple System Atrophy
- Parkinson's Disease
|
|
Observational
|
|
- Vanderbilt University Medical Center
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Time Perspective: Prospective
|
- Final Diagnosis (pre vs post ganglionic autonomic failure) based on clinical criteria.
|
50 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01316666 |
101311
U54NS065736 |
6103 |
March 2011 |
December 2016 |
December 2016 |
March 16, 2011 |
January 6, 2017 |
|
- Beth Israel Deaconess Medical Center (Harvard)
Boston, Massachusetts, United States - Mayo Clinic
Rochester, Minnesota, United States - New York University
New York, New York, United States - Vanderbilt University
Nashville, Tennessee, United States
|
|
| 5 |
NCT00738062 |
Completed
Has Results |
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) |
- Neurogenic Orthostatic Hypotension
- Non-Diabetic Autonomic Neuropathy
- Multiple System Atrophy
- Dopamine Beta Hydroxylase Deficiency
|
- Drug: Droxidopa
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Orthostatic Hypotension Questionnaire Composite Score (OHQ)
- Change in Orthostatic Hypotension Daily Activities (OHDAS) Score
- Change in Orthostatic Hypotension Symptom Assessment (OHSA) Composite Score
- (and 5 more...)
|
103 |
All |
18 Years and older (Adult, Older Adult) |
NCT00738062 |
Droxidopa NOH303 |
NOH303 |
January 2008 |
December 2010 |
December 2010 |
August 20, 2008 |
May 16, 2014 |
May 16, 2014 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Dedicated Clinical Research
Litchfield Park, Arizona, United States - Xenoscience Inc.
Phoenix, Arizona, United States - (and 51 more...)
|
|
| 6 |
NCT01146548 |
Completed |
Fluoxetine in Multiple System Atrophy Patients |
|
|
Interventional
|
Phase 2 |
- University Hospital, Toulouse
- Clinical Research Center, Toulouse
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Supportive Care
|
- primary efficacy endpoint
- secondary efficacy endpoints
|
87 |
All |
30 Years to 80 Years (Adult, Older Adult) |
NCT01146548 |
0720101 |
MSA-Fluox |
May 2008 |
June 2011 |
September 2011 |
June 17, 2010 |
March 26, 2015 |
|
- hospital center of Aix enProvence
Aix en Provence, France - Hospital Gabriel Montpied
Clermont-Ferrand, France - University Hospital Henri Mondor
Creteil, France - (and 11 more...)
|
|
| 7 |
NCT02796209 |
Recruiting |
Norepinephrine Transporter Blockade, Autonomic Failure |
- Multiple System Atrophy (MSA)
|
- Drug: Atomexetine
- Drug: Placebo
|
Interventional
|
Phase 2 |
- New York University School of Medicine
- Vanderbilt University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Change from Baseline of Orthostatic Hypotension Questionnaire (OHQ) Score
|
40 |
All |
40 Years to 80 Years (Adult, Older Adult) |
NCT02796209 |
16-00453 |
|
May 2016 |
April 2020 |
December 2020 |
June 10, 2016 |
October 6, 2017 |
|
- New York University School of Medicine
New York, New York, United States
|
|
| 8 |
NCT00782340 |
Completed
Has Results |
A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa |
- Symptomatic Neurogenic Orthostatic Hypotension (NOH)
- Non-diabetic Neuropathy
- Primary Autonomic Failure
- Dopamine Beta Hydroxylase Deficiency
|
- Drug: Placebo
- Drug: Droxidopa
|
Interventional
|
Phase 3 |
- Chelsea Therapeutics
- Chiltern International Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in Orthostatic Hypotension Questionnaire Score (OHQ)
- Change in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score)
- Change in Orthostatic Hypotension Symptom Assessment (OHSA Composite) Score
- (and 6 more...)
|
263 |
All |
18 Years and older (Adult, Older Adult) |
NCT00782340 |
Droxidopa NOH301 |
NOH301 |
September 2008 |
September 2010 |
September 2010 |
October 31, 2008 |
May 16, 2014 |
May 16, 2014 |
- North Alabama Neuroscience
Huntsville, Alabama, United States - Mayo Clinic-Arizona
Scottsdale, Arizona, United States - Arkansas Cardiology
Little Rock, Arkansas, United States - (and 18 more...)
|
|
| 9 |
NCT02586623 |
Recruiting |
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension |
- Symptomatic Neurogenic Orthostatic Hypotension
|
- Drug: Droxidopa capsules
- Drug: Placebo capsules
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time-to-intervention
- Time to all cause discontinuation
- Mean change in OHSA item #1 score from Randomization (Visit 6) to all post-Randomization visits
- (and 4 more...)
|
482 |
All |
18 Years and older (Adult, Older Adult) |
NCT02586623 |
16306A
NOH402 |
RESTORE |
February 2016 |
March 2021 |
March 2021 |
October 26, 2015 |
September 15, 2017 |
|
- 21st Century Neurology
Phoenix, Arizona, United States - Movement Disorders Center of Arizona
Scottsdale, Arizona, United States - Center For Neurosciences
Tucson, Arizona, United States - (and 82 more...)
|
|
| 10 |
NCT00633880 |
Completed
Has Results |
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) |
- Symptomatic Neurogenic Orthostatic Hypotension (NOH)
- Non-diabetic Neuropathy
- Primary Autonomic Failure
- Dopamine Beta Hydroxylase Deficiency
|
- Drug: Placebo
- Drug: Droxidopa
|
Interventional
|
Phase 3 |
- Chelsea Therapeutics
- Chiltern International Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)
- Change in Fatigue (OHSA Item 4)
- Change in Weakness (OHSA Item 3)
- (and 7 more...)
|
181 |
All |
18 Years and older (Adult, Older Adult) |
NCT00633880 |
Droxidopa NOH302 |
NOH302 |
January 2008 |
August 2009 |
September 2009 |
March 12, 2008 |
May 20, 2014 |
May 20, 2014 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Dedicated Clinical Research
Litchfield Park, Arizona, United States - Xenoscience Inc.
Phoenix, Arizona, United States - (and 51 more...)
|
|
| 11 |
NCT02307526 |
Completed
Has Results |
Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI |
|
- Drug: Pyridostigmine Bromide
- Device: Tilt table test
|
Interventional
|
Phase 2 |
- James J. Peters Veterans Affairs Medical Center
|
U.S. Fed |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Systolic Blood Pressure
- Diastolic Blood Pressure
- Heart Rate
|
10 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02307526 |
WEC-11-04 |
|
January 2011 |
March 2015 |
March 2015 |
December 4, 2014 |
July 21, 2017 |
July 21, 2017 |
- Kessler Institute for Rehabilitation
West Orange, New Jersey, United States
|
|
| 12 |
NCT00046475 |
Completed
Has Results |
A Study for Patients With Neurogenic Orthostatic Hypotension |
|
- Drug: Midodrine Hydrochloride
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Post-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale
- Re-analysis of The Post-treatment Score For Item 1 of The OHSA Scale, Excluding Two Sites
- Post-treatment OHSA Item 1 Score of United States (US) Participants With Mild/Moderate Disease According to The Clinical Global Impressions-Severity (CGI-S) Scale
- (and 13 more...)
|
140 |
All |
18 Years and older (Adult, Older Adult) |
NCT00046475 |
20,762-401 |
|
January 2002 |
|
October 2004 |
October 2, 2002 |
June 8, 2015 |
May 12, 2015 |
- North Alabama Neuroscience Research
Huntsville, Alabama, United States - Dr. Harry Pepe & Associates, Inc.
Miramar, Florida, United States - Suncoast Neuroscience Associates, Inc.
St. Petersburg, Florida, United States - (and 12 more...)
|
|
| 13 |
NCT02429557 |
Recruiting |
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure |
- Orthostatic Hypotension
- Pure Autonomic Failure
- Multiple System Atrophy
- Autonomic Failure
|
- Other: Abdominal compression
- Other: Sham abdominal compression
- Drug: Placebo pill
- Drug: midodrine
|
Interventional
|
Phase 1 |
- Vanderbilt University
- Vanderbilt University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Other
|
- Stroke volume
- Systolic blood pressure
- Splanchnic vascular volume
|
20 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02429557 |
140634 |
|
April 2015 |
April 2020 |
July 2020 |
April 29, 2015 |
January 25, 2018 |
|
- Vanderbilt University
Nashville, Tennessee, United States
|
|
| 14 |
NCT00046163 |
Terminated |
A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension |
|
- Drug: midodrine hydrochloride (ProAmatine®)
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT00046163 |
SPD 426-403 |
|
September 2002 |
|
August 2003 |
September 23, 2002 |
November 6, 2007 |
|
- Suncoast Neuroscience Associates, Inc.
St. Petersburg, Florida, United States - Neurological Associates of Delaware Valley
Upland, Pennsylvania, United States - Diabetes & Glandular Disease Research Associates, PA,
San Antonio, Texas, United States
|
|
| 15 |
NCT01799915 |
Recruiting |
Natural History Study of Synucleinopathies |
- Patients With Synucleinopathies
- Neurogenic Orthostatic Hypotension
- Pure Autonomic Failure
- (and 5 more...)
|
|
Observational
|
|
- New York University School of Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To create a database of primary autonomic disorders that will serve as a phenotyping core.
- To define the natural history of neurogenic orthostatic hypotension and identify predictive biomarkers of autonomic disorders
|
800 |
All |
18 Years and older (Adult, Older Adult) |
NCT01799915 |
08-1408 |
|
June 2011 |
July 2020 |
July 2020 |
February 27, 2013 |
January 25, 2018 |
|
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - University of Michigan
Ann Arbor, Michigan, United States - Mayo Clinic
Rochester, Minnesota, United States - (and 5 more...)
|
|
| 16 |
NCT00004478 |
Completed |
Droxidopa in Treating Patients With Neurogenic Hypotension |
- Shy-Drager Syndrome
- Orthostatic Hypotension
|
|
Interventional
|
Not Applicable |
- Icahn School of Medicine at Mount Sinai
- Office of Rare Diseases (ORD)
|
Other |
- Primary Purpose: Treatment
|
|
|
All |
20 Years and older (Adult, Older Adult) |
NCT00004478 |
199/14180
MTS-GCO-98-243-3-NE |
|
March 1999 |
March 2006 |
March 2006 |
October 19, 1999 |
September 18, 2008 |
|
- New York University School of Medicine
New York, New York, United States
|
|
| 17 |
NCT02705755 |
Active, not recruiting |
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) |
- Neurogenic Orthostatic Hypotension
- Multiple System Atrophy (MSA) With Orthostatic Hypotension
- Pure Autonomic Failure
- (and 5 more...)
|
- Drug: TD-9855
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Theravance Biopharma R & D, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Seated systolic blood pressure
- Adverse Events
- Orthostatic hypotension symptoms
|
34 |
All |
40 Years and older (Adult, Older Adult) |
NCT02705755 |
0145 |
|
May 2016 |
July 2018 |
December 2018 |
March 10, 2016 |
May 22, 2018 |
|
- Collaborative Neuroscience Network, LLC.
Long Beach, California, United States - Quest Research Institute
Farmington Hills, Michigan, United States - Hassman Research Institute
Berlin, New Jersey, United States - (and 3 more...)
|
|
| 18 |
NCT02701036 |
Recruiting |
Sporadic Degenerative Ataxia With Adult Onset: Natural History Study |
- Late Onset Sporadic Cerebellar Ataxia
|
|
Observational
|
|
- Ataxia Study Group
- German Center for Neurodegenerative Diseases (DZNE)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Scale for the assessment and rating of ataxia (SARA)
- Inventory of non-ataxia signs (INAS)
- spinocerebellar ataxia functional index (SCAFI)
- (and 6 more...)
|
300 |
All |
40 Years and older (Adult, Older Adult) |
NCT02701036 |
SPORTAX 010/05 |
SPORTAX-NHS |
April 2010 |
December 2030 |
December 2030 |
March 8, 2016 |
June 29, 2017 |
|
- Department of Neurology, Medical University, Innsbruck
Innsbruck, Austria - Universitätsmedizin Berlin Charité
Berlin, Germany - Department of Neurology, University of Bonn
Bonn, Germany - (and 11 more...)
|
|
| 19 |
NCT01136213 |
Completed |
Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study |
|
- Radiation: PET (Positron Emission Tomography) Study
- Other: Brain MRI (magnetic resonance imaging)
- Drug: Fluoxétine / Placebo
|
Observational
|
|
- University Hospital, Bordeaux
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- 18F-MPPF binding potential - Biding potential (BP) under placebo in the raphe nucleus
- 18F-MPPF binding potential - Biding potential (BP) in other brain areas
- Clinical parameters (motor handicap, orthostatic hypotension, quality of life, sleep, pain, tiredness)
- (and 2 more...)
|
53 |
All |
30 Years to 80 Years (Adult, Older Adult) |
NCT01136213 |
CHUBX 2008/01 |
SEROTAMS |
April 2010 |
March 2016 |
March 2016 |
June 3, 2010 |
August 4, 2017 |
|
- CHU de Bordeaux
Bordeaux, France - CHU Limoges
Limoges, France - CHU de Toulouse
Toulouse, France
|
|
| 20 |
NCT03042988 |
Recruiting |
Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension |
- Hypertension
- Pure Autonomic Failure
- Multiple System Atrophy
- Autonomic Failure
|
- Other: Heating pad
- Other: Sham control
|
Interventional
|
Not Applicable |
- Vanderbilt University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Systolic blood pressure
- Orthostatic Tolerance the following morning
|
20 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03042988 |
VR22699
141523 |
|
January 30, 2017 |
January 30, 2021 |
July 30, 2021 |
February 3, 2017 |
January 25, 2018 |
|
- Autonomic Dysfunction Center/ Vanderbilt University Medical Center
Nashville, Tennessee, United States
|
|
| 21 |
NCT02726711 |
Recruiting |
Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic |
- Multiple System Atrophy
- Orthostatic Hypotension
- Supine Hypertension
|
- Drug: Trimethaphan
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Vanderbilt University
- Vanderbilt University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Basic Science
|
- The percentage of increase of the y intercept of the P-V relationship
|
32 |
All |
40 Years to 80 Years (Adult, Older Adult) |
NCT02726711 |
151947 |
|
April 2016 |
March 2021 |
March 2021 |
April 4, 2016 |
January 25, 2018 |
|
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
|
|
| 22 |
NCT01927055 |
Terminated
Has Results |
A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy |
- Symptomatic Neurogenic Orthostatic Hypotension
- Parkinson's Disease
- Multiple Systems Atrophy
- (and 2 more...)
|
- Drug: Droxidopa
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)
|
61 |
All |
18 Years and older (Adult, Older Adult) |
NCT01927055 |
NOH401 |
|
November 2013 |
February 2015 |
February 2015 |
August 22, 2013 |
January 8, 2016 |
January 8, 2016 |
- NYU Langone Medical Center
New York, New York, United States - Information on additional locations involved in this clinical trial contact Chelsea Therapeutics
Charlotte, North Carolina, United States - Wisconsin Institute for Neurology and Sleep Disorders
Milwaukee, Wisconsin, United States
|
|
| 23 |
NCT02417415 |
Recruiting |
Local Heat Stress in Autonomic Failure Patients With Supine Hypertension |
- Hypertension
- Pure Autonomic Failure
- Multiple System Atrophy
- Autonomic Failure
|
- Other: Passive heat stress
- Other: Control (non-heating)
|
Interventional
|
Not Applicable |
- Vanderbilt University
- Vanderbilt University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Systolic blood pressure
- Hemodynamic measures
|
21 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02417415 |
141523 |
|
April 2015 |
April 2018 |
September 2018 |
April 15, 2015 |
January 25, 2018 |
|
- Vanderbilt University
Nashville, Tennessee, United States
|
|
| 24 |
NCT00223717 |
Completed |
Treatment of Supine Hypertension in Autonomic Failure |
|
- Drug: Clonidine
- Drug: Nitroglycerin transdermal
- Drug: Dipyridamole/ Aspirin (Aggrenox)
- (and 21 more...)
|
Interventional
|
Phase 1 |
- Vanderbilt University
- Vanderbilt University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Decrease in supine systolic blood pressure
- Decrease in pressure natriuresis
|
152 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00223717 |
010189 |
|
January 2001 |
January 2017 |
January 2017 |
September 22, 2005 |
October 13, 2017 |
|
- Vanderbilt University
Nashville, Tennessee, United States
|
|
| 25 |
NCT02897063 |
Recruiting |
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure |
- Autonomic Failure
- Pure Autonomic Failure
- Multiple System Atrophy
- (and 2 more...)
|
- Drug: Droxidopa
- Drug: Midodrine
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Vanderbilt University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
|
34 |
All |
40 Years to 80 Years (Adult, Older Adult) |
NCT02897063 |
160255 |
|
September 2016 |
March 2021 |
August 2021 |
September 12, 2016 |
January 25, 2018 |
|
- Autonomic Dysfunction Center/ Vanderbilt University Medical Center
Nashville, Tennessee, United States
|
|
| 26 |
NCT00977665 |
Completed
Has Results |
Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) |
|
- Drug: rasagiline mesylate
- Drug: placebo
|
Interventional
|
Phase 2 |
- Teva Pharmaceutical Industries
- H. Lundbeck A/S
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline to Week 48/Termination Visit in the Total Unified Multiple System Atrophy Rating Scale (UMSARS Part I and II)
- Clinical Global Impression Improvement (CGI-I) at Week 48/Termination Visit
- Change From Baseline to Week 24 in Total Unified Multiple System Atrophy Rating Scale (UMSARS) Score
- (and 11 more...)
|
174 |
All |
30 Years and older (Adult, Older Adult) |
NCT00977665 |
MSA-RAS-202
2009-014644-11 |
|
December 2009 |
October 2011 |
October 2011 |
September 16, 2009 |
February 26, 2015 |
February 26, 2015 |
- Teva Investigational Site 1004
Irvine, California, United States - Teva Investigational Site 1014
La Jolla, California, United States - Teva Investigational Site 1006
Sunnyvale, California, United States - (and 44 more...)
|
|
| 27 |
NCT02591173 |
Recruiting |
Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure |
- Autonomic Nervous System Disorders
- Pure Autonomic Failure
- Shy-Drager Syndrome
- Orthostatic Hypotension, Dysautonomic
|
- Drug: Angiotensin-(1-7)
- Drug: Saline
|
Interventional
|
Early Phase 1 |
- Vanderbilt University
- Vanderbilt University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Blood Presure
- Heart Rate
- Cardiac Output
- (and 5 more...)
|
22 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02591173 |
151461 |
|
February 2016 |
December 2018 |
December 2018 |
October 29, 2015 |
January 25, 2018 |
|
- Vanderbilt University
Nashville, Tennessee, United States
|
|
| 28 |
NCT02021903 |
Recruiting |
Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies |
|
- Other: V1: HGPO + meal and V2: placebo + meal
- Other: V1: placebo 75mg + meal and V2: HGPO 75mg + meal
|
Interventional
|
Not Applicable |
- University Hospital, Toulouse
- Ministry of Health, France
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Diagnostic
|
- Rate of patients presenting a "sleep onset"
- rate of patients without arterial hypotension nor a sleep episode within 120 minutes after oral solution administration ;
- rate of patients that show a sleep episode but without arterial hypotension within 120 minutes after oral solution administration ;
- (and 3 more...)
|
24 |
All |
35 Years to 85 Years (Adult, Older Adult) |
NCT02021903 |
1120008 |
HYPOSOMNPARK |
May 2012 |
December 2018 |
June 2019 |
December 27, 2013 |
May 31, 2018 |
|
- UHBordeaux
Bordeaux, France - UHToulouse
Toulouse, France
|
|
Create an RSS feed from your search for:
Download the search results for: